Abstract: A sealing element for a rotary piston machine for sealing a lever is provided which is guided in an annular gap and is rotatable around a rotational axis, wherein the sealing element is rotationally symmetrical relative to the rotational axis, characterized in that the sealing element comprises a dynamic region and a static region, wherein the dynamic region has an axial sealing face being directed towards the annular gap, and a radial sealing face being directed towards the interior of an annular channel of the rotary piston machine, which annular channel surrounds the annular gap; and wherein the static region serves to fix the sealing element to the rotary piston machine, and wherein there is formed in the static region a channel, to which a fluid can be supplied.

Abstract: A sensor arrangement for a wheelchair wheel that has a running wheel with a hub and a hand rim includes a running wheel fastening arrangement that is fastened to the running wheel, a hand rim fastening arrangement that is fastened to the hand rim and at least one sensor that detects a movement of the hand rim fastening arrangement relative to the running wheel fastening arrangement. Two restoring elements are provided on the running wheel fastening arrangement and rest against the hand rim arrangement with a prestressing force at least in the zero position. Both restoring elements rest against at least one stop of the running wheel fastening arrangement in the zero position of the sensor arrangement.

Abstract: A sealing element for a rotary piston machine for sealing a lever is provided which is guided in an annular gap and is rotatable around a rotational axis, wherein the sealing element is rotationally symmetrical relative to the rotational axis, characterized in that the sealing element comprises a dynamic region and a static region, wherein the dynamic region has an axial sealing face being directed towards the annular gap, and a radial sealing face being directed towards the interior of an annular channel of the rotary piston machine, which annular channel surrounds the annular gap; and wherein the static region serves to fix the sealing element to the rotary piston machine, and wherein there is formed in the static region a channel, to which a fluid can be supplied.

Abstract: A sensor arrangement for a wheelchair wheel that has a running wheel with a hub and a hand rim includes a running wheel fastening arrangement that is fastened to the running wheel, a hand rim fastening arrangement that is fastened to the hand rim and at least one sensor that detects a movement of the hand rim fastening arrangement relative to the running wheel fastening arrangement. Two restoring elements are provided on the running wheel fastening arrangement and rest against the hand rim arrangement with a prestressing force at least in the zero position. Both restoring elements rest against at least one stop of the running wheel fastening arrangement in the zero position of the sensor arrangement.

Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumour tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and ?v?3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumour cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.

Abstract: The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumor tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and ?v?3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.

Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and ?v?3 integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.

Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and ?v?3 integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.

Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1) wherein R1, R2, U, V, A, B, W, R3, C and R4 have the meaning as defined in the claims.

Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases.

Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases

Abstract: An optimization method for a fluence pattern to be provided via a radiotherapeutic apparatus comprising a multi-leaf collimator comprises an iteration of a progressive solution (such as a gradient approach) of the fluence profile, at least some iterations including a weighted penalty function which varies between solutions favored by the collimator design and solutions not so favored, later iterations including the penalty function at a greater weight. Thus, the penalty function represents locally preferred solutions derived from the constraints of the multi-leaf collimator (MLC). As the iteration progresses, the greater weight assigned to the penalty function drives the method towards a solution which is possible given the MLC constraints. However, the lesser weight attached in the early stages of the iteration allows the method to settle towards a genuinely preferred solution.

Abstract: The present invention relates to compounds of the general formula (I), their preparation and use as pharmaceutical compositions asintegrin antagonists, especially as ?4? and/or ?4?7 ?and/or ?9?1 intergrin antagonists and in particular for the production of pharmaceutical compositions suitable for the inhibition or the prevention of cell adhesion and cell-adhesion mediated disorders. Examples are the treatment and the prophylaxis of atherosclerosis, asthma, chronic obstructive pulmonary disease (COPD), allergies, diabetes, inflammatory bowel disease, multiple sclerosis, myocardial ischemia, rheumatoid arthritis, transplant rejection and other inflammatory, autoimmune and immune disorders.

Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases.

Abstract: The present invention relates to compounds of the general formula (I), 1

Abstract: The present invention relates to a compound of the general formula (I), wherein R1 together with the C atom to which it is attached, and R2 together with the N atom to which it is attached, form a piperidinyl ring; X represents a bond, oxygen or —NR12—; and Y represents oxygen; pharmaceutical compositions containing such a compound, as well as the use of such a compound for the production of pharmaceutical compositions, and for the treatment of inflammatory, auto-immune and immune diseases.

Abstract: An optimisation method for a fluence pattern to be provided via a radiotherapeutic apparatus comprising a multi-leaf collimator comprises an iteration of a progressive solution (such as a gradient approach) of the fluence profile, at least some iterations including a weighted penalty function which varies between solutions favoured by the collimator design and solutions not so favoured, later iterations including the penalty function at a greater weight. Thus, the penalty function represents locally preferred solutions derived from the constraints of the multi-leaf collimator (MLC). As the iteration progresses, the greater weight assigned to the penalty function drives the method towards a solution which is possible given the MLC constraints. However, the lesser weight attached in the early stages of the iteration allows the method to settle towards a genuinely preferred solution.

Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases.

Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases.

Abstract: The present invention relates to compounds of general formula (I), wherein the residues R represent organic radicals, X represents a bond, oxygen or —NR12 and Y represents oxygen or sulfur, processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory, autoimmune and immune diseases.